"Everolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of sirolimus and an inhibitor of TOR SERINE-THREONINE KINASES. It is used to prevent GRAFT REJECTION in heart and kidney transplant patients by blocking cell proliferation signals. It is also an ANTINEOPLASTIC AGENT.
| Descriptor ID |
D000068338
|
| MeSH Number(s) |
D02.540.505.760.500
|
| Concept/Terms |
Everolimus- Everolimus
- SDZ RAD
- RAD, SDZ
- SDZ-RAD
- 40-O-(2-hydroxyethyl)-rapamycin
|
Below are MeSH descriptors whose meaning is more general than "Everolimus".
Below are MeSH descriptors whose meaning is more specific than "Everolimus".
This graph shows the total number of publications written about "Everolimus" by people in this website by year, and whether "Everolimus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 2 | 2 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 4 | 4 |
| 2008 | 0 | 5 | 5 |
| 2009 | 0 | 4 | 4 |
| 2010 | 0 | 7 | 7 |
| 2011 | 0 | 8 | 8 |
| 2012 | 0 | 10 | 10 |
| 2013 | 0 | 12 | 12 |
| 2014 | 1 | 14 | 15 |
| 2015 | 9 | 14 | 23 |
| 2016 | 11 | 4 | 15 |
| 2017 | 11 | 7 | 18 |
| 2018 | 6 | 4 | 10 |
| 2019 | 2 | 4 | 6 |
| 2020 | 5 | 2 | 7 |
| 2021 | 6 | 8 | 14 |
| 2022 | 1 | 5 | 6 |
| 2023 | 1 | 4 | 5 |
| 2024 | 3 | 2 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Everolimus" by people in Profiles.
-
TCA metabolism regulates DNA hypermethylation in LPS and Mycobacterium tuberculosis-induced immune tolerance. Proc Natl Acad Sci U S A. 2024 Oct 08; 121(41):e2404841121.
-
Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 Aug 01; 7(8):e2425288.
-
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial. Eur Urol. 2024 Sep; 86(3):258-264.
-
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nat Commun. 2024 Mar 19; 15(1):2446.
-
Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning. Angew Chem Int Ed Engl. 2024 03 18; 63(12):e202319925.
-
Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study. ESMO Open. 2023 Dec; 8(6):101609.
-
Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration. Oncologist. 2023 07 05; 28(7):575-583.
-
Survival Outcomes in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy. JAMA Netw Open. 2023 05 01; 6(5):e2313017.
-
Safety and Efficacy of Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Second-Generation Drug-Eluting Stents in Real-World Practice. J Korean Med Sci. 2023 Feb 06; 38(5):e34.
-
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer. Breast Cancer Res Treat. 2023 Apr; 198(2):217-229.